-continued

```
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
            180                 185                 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
        195                 200                 205

Ser Phe Asn Arg Gly Glu Cys
    210                 215
```

What is claimed is:

1. A pharmaceutical formulation comprising: (i) an anti-human Activin A antibody, or antigen-binding portion thereof; (ii) a buffer at pH of 6.3±0.3; (iii) an organic cosolvent; and (iv) one or more thermal stabilizers.

2. The pharmaceutical formulation of claim **1**, wherein the antibody, or the antigen-binding portion thereof, comprises the following six CDR sequences:

(a) an HCDR1 having the sequence GGSFSSHF (SEQ ID NO.: 1);

(b) an HCDR2 having the sequence ILYTGGT (SEQ ID NO.: 2);

(c) an HCDR3 having the sequence ARARSGITFTGIIVPGSFDI (SEQ ID NO.: 3);

(d) an LCDR1 having the sequence QSVSSSY (SEQ ID NO.: 4);

(e) an LCDR2 having the sequence GAS (SEQ ID NO.: 5); and

(f) an LCDR3 having the sequence QQYGSSPWT (SEQ ID NO.: 6).

3. The pharmaceutical formulation of claim **2**, wherein the antibody has a molecular weight of about 145,235.3 Da.

4. The pharmaceutical formulation of claim **3**, wherein the antibody, or the antigen-binding portion thereof, concentration is 60 mg/mL±6 mg/mL.

5. The pharmaceutical formulation of claim **1**, wherein the buffer is a histidine buffer.

6. The pharmaceutical formulation of claim **5**, wherein the histidine concentration is 10 mM±2 mM.

7. The pharmaceutical formulation of claim **1**, wherein the organic cosolvent is polysorbate 20.

8. The pharmaceutical formulation of claim **7**, wherein the polysorbate 20 concentration is 0.05% w/v±0.025%.

9. The pharmaceutical formulation of claim **1**, wherein the one or more thermal stablilizers comprise sucrose and arginine.

10. The pharmaceutical formulation of claim **9**, wherein the sucrose concentration is 5%±1% (w/v) and the Arginine concentration is 70 mM±14 mM.

11. The pharmaceutical formulation of claim **1**, comprising 60 mg/mL±6 mg/mL antibody, 10 mM±2 mM histidine, pH 6.3±0.3, 0.05% w/v±0.025% polysorbate 20, 5% w/v±1% sucrose, and 70 mM±14 mM Arginine.

12. The pharmaceutical formulation of claim **2**, wherein after 56 days of storage at 40° C. and 75% relative humidity (RH), at least 90% of the antibody, or the antigen-binding portion thereof, has native conformation, or at least 30% of the antibody, or the antigen-binding portion thereof, is the main charge form.

13. The pharmaceutical formulation of claim **2**, wherein after 56 days of storage at 40° C. and 75% RH, at least 93% of the antibody, or the antigen-binding portion thereof, has native conformation, or at least 34.5% of the antibody, or the antigen-binding portion thereof, is the main charge form.

14. The pharmaceutical formulation of claim **2**, wherein after 56 days of storage at 40° C. and 75% RH, at least 97% of the antibody, or the antigen-binding portion thereof, has native conformation, or at least 45% of the antibody, or the antigen-binding portion thereof, is the main charge form.

15. The pharmaceutical formulation of claim **2**, wherein after six months of storage at 25° C. and 60% RH, at least 90% of the antibody, or the antigen-binding portion thereof, has native conformation, or at least 40% of the antibody, or the antigen-binding portion thereof, is the main charge form.

16. The pharmaceutical formulation of claim **2**, wherein after six months of storage at 25° C. and 60% RH, at least 95% of the antibody, or the antigen-binding portion thereof, has native conformation, or at least 45% of the antibody, or the antigen-binding portion thereof, is the main charge form.

17. The pharmaceutical formulation of claim **2**, wherein after six months of storage at 25° C. and 60% RH, at least 98% of the antibody, or the antigen-binding portion thereof, has native conformation, or at least 50% of the antibody, or the antigen-binding portion thereof, is the main charge form.

18. The pharmaceutical formulation claim **2**, wherein after 12 months of storage at 2-8° C., at least 94% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 45% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 100% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

19. The pharmaceutical formulation claim **2**, wherein after 12 months of storage at 2-8° C., at least 96% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 50% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 100% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

20. The pharmaceutical formulation claim **2**, wherein after 12 months of storage at 2-8° C., at least 98% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 55% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 100% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

21. The pharmaceutical formulation claim **2**, wherein after 18 months of storage at 2-8° C., at least 94% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 45% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or